- Trials with a EudraCT protocol (61)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
61 result(s) found for: Gallbladder Cancer AND Gallbladder Disease.
Displaying page 1 of 4.
| EudraCT Number: 2017-001538-25 | Sponsor Protocol Number: AIO-HEP-0117 | Start Date*: 2018-03-12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A randomized phase II trial of durvalumab and tremelimumab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with cholangio- and gallbl... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: advanced, unresectable and/or metastatic cholangio- and gallbladder carcinoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2012-001705-24 | Sponsor Protocol Number: HE37/12 | Start Date*: 2013-02-20 | |||||||||||||||||||||
| Sponsor Name:Hellenic Cooperative Oncology Group | |||||||||||||||||||||||
| Full Title: Phase II single-arm study of first line treatment with gemcitabine and pazopanib in patients with inoperable locally advanced or metastatic biliary tree cancer (cholangiocarcinoma or gallbladder ca... | |||||||||||||||||||||||
| Medical condition: Inoperable locally advanced or metastatic cancer of the biliary tree (cholangiocarcinoma and gallbladder carcinoma) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GR (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2010-018850-11 | Sponsor Protocol Number: MHH_CCA_AG54 | Start Date*: 2011-04-15 | ||||||||||||||||
| Sponsor Name:Medizinische Hochschule Hannover (MHH) | ||||||||||||||||||
| Full Title: Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcinomas - a randomized clinical phase II study - PiCCA Study | ||||||||||||||||||
| Medical condition: cholangiocarcinoma / gall bladder carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2012-005078-70 | Sponsor Protocol Number: ACTICCA-1 | Start Date*: 2014-01-16 | ||||||||||||||||
| Sponsor Name:University Medical Center Hamburg-Eppendorf | ||||||||||||||||||
| Full Title: Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) ... | ||||||||||||||||||
| Medical condition: Cholangiocarcinoma and gallbladder carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Restarted) NL (Ongoing) GB (GB - no longer in EU/EEA) DK (Completed) AT (Ongoing) IT (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2017-004444-38 | Sponsor Protocol Number: GAIN/GEM/CIS | Start Date*: 2019-01-11 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Krankenhaus Nordwest gGmbH | ||||||||||||||||||||||||||||||||||||||
| Full Title: Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally det... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: incidental gallbladder carcinoma (IGBC) or biliary tract cancer (BTC) (intrahepatic cholangiocarcinoma (ICC)/ extrahepatic cholangiocarcinoma (ECC)) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Ongoing) AT (Ongoing) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-000179-36 | Sponsor Protocol Number: MS200647_0054 | Start Date*: 2021-12-16 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Merck KGaA | ||||||||||||||||||||||||||||||||||||||
| Full Title: An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Bintrafusp alfa (M7824) Clinical Studies | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), cervical cancer, and triple-negative breast cancer (TNBC) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) ES (Ongoing) IT (Ongoing) DE (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-002389-41 | Sponsor Protocol Number: ADJUBIL | Start Date*: 2022-02-25 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: biliary tract cancer | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2016-000084-16 | Sponsor Protocol Number: NC-6004-004A | Start Date*: 2016-11-24 | |||||||||||||||||||||
| Sponsor Name:NanoCarrier Co, Ltd | |||||||||||||||||||||||
| Full Title: A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Squamous Non-Small Cell Lung, Biliary Tract, and Blad... | |||||||||||||||||||||||
| Medical condition: Advanced solid tumors and first-line metastatic squamous NSCLC; first-line metastatic or locally advanced cholangiocarcinoma, gallbladder cancer, or ampullary cancer (biliary tract cancer); and fir... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: BG (Completed) PL (Completed) IT (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2020-004873-29 | Sponsor Protocol Number: SGNTUC-019 | Start Date*: 2021-05-31 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Seagen Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) PL (Completed) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-001992-35 | Sponsor Protocol Number: MS200647_0055 | Start Date*: 2020-04-30 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Merck Healthcare KGaA | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp alfa (M7824) as First-line Treatment of Biliary Tract Cancer | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Biliary Tract Cancer | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) FR (Prematurely Ended) PL (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-003707-19 | Sponsor Protocol Number: MS200647_0047 | Start Date*: 2019-04-15 | ||||||||||||||||||||||||||
| Sponsor Name:Merck KGaA | ||||||||||||||||||||||||||||
| Full Title: A Phase II, Multicenter, Open label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolera... | ||||||||||||||||||||||||||||
| Medical condition: Biliary Tract Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2010-021240-18 | Sponsor Protocol Number: ARHSG062010 | Start Date*: 2011-04-19 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA S. GERARDO DI MONZA | |||||||||||||
| Full Title: Peritoneal nebulization of Ropivacaine for pain control after laparoscopic colectomy | |||||||||||||
| Medical condition: Elective Laparoscopic colectomy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-002382-30 | Sponsor Protocol Number: RDD677 | Start Date*: 2015-03-13 | |||||||||||||||||||||
| Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust | |||||||||||||||||||||||
| Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with resectable proximal biliary tract cancer: | |||||||||||||||||||||||
| Medical condition: Resectable Biliary Tract Carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2016-003709-33 | Sponsor Protocol Number: AIO-HEP-0116 | Start Date*: 2017-05-04 | |||||||||||||||||||||||||||||||
| Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||||||||||||
| Full Title: A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies | |||||||||||||||||||||||||||||||||
| Medical condition: advanced, unresectable and metastatic cholangio- and gallbladder carcinoma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2022-000222-24 | Sponsor Protocol Number: CYC140-101 | Start Date*: 2022-06-07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Cyclacel Pharmaceuticals | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS AND EFFICACY OF CYC140, AN ORAL PLK1 INHIBITOR, IN SUBJECTS WITH ADVANCED SOLID TUMORS AND LYMPHOMA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: ADVANCED SOLID TUMORS AND LYMPHOMA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-013408-30 | Sponsor Protocol Number: 2009-013408-30 | Start Date*: 2010-08-23 | |||||||||||||||||||||
| Sponsor Name:University College London | |||||||||||||||||||||||
| Full Title: Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancers | |||||||||||||||||||||||
| Medical condition: biliary tract carcinomas (including gallbladder cancer and cholangiocarcinomas) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2007-005850-22 | Sponsor Protocol Number: 62202-788 | Start Date*: 2008-07-28 | |||||||||||
| Sponsor Name:BGDO | |||||||||||||
| Full Title: GEMCITABINE AND CETUXIMAB IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER: A BGDO MULTICENTER PHASE II STUDY | |||||||||||||
| Medical condition: Patients with advanced biliary tract cancer, excluding gallbladder cancer, where surgery is not feasible. | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-005796-34 | Sponsor Protocol Number: CC-GEMSO-2007 | Start Date*: 2008-03-19 | |||||||||||
| Sponsor Name:Universität Mainz, I. Medizinische Klinik und Poliklinik | |||||||||||||
| Full Title: A randomized, double-blind, multicenter phase II trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemo-naive advanced or metastatic adenocarcinoma of the bili... | |||||||||||||
| Medical condition: Patients with Adenocarcinoma of the gallbladder or intrahepatic bile ducts or histologically proven hepatic metastases of an earlier resected and histologically proven biliary tract cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-001200-20 | Sponsor Protocol Number: CSET 1287 | Start Date*: 2007-06-01 |
| Sponsor Name:Institut Gustave Roussy | ||
| Full Title: A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer | ||
| Medical condition: adenocarcinoma of the biliary tract ( gallbladder, intra and/ or extrahepatic bile ducts, ampulla of Vater) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-005579-10 | Sponsor Protocol Number: A-93-52030-325 | Start Date*: 2016-02-26 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:IPSEN S.P.A. | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: EFFICACY AND SAFETY OF LANREOTIDE ATG 120 MG IN COMBINATION WITH TEMOZOLOMIDE IN SUBJECTS WITH PROGRESSIVE WELL DIFFERENTIATED THORACIC NEUROENDOCRINE TUMORS | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: progressive well differentiated thoracic neuroendocrine tumors | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
